Compare EIG & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | DRUG |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.6M | 707.1M |
| IPO Year | 2006 | 2020 |
| Metric | EIG | DRUG |
|---|---|---|
| Price | $45.54 | $70.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $129.25 |
| AVG Volume (30 Days) | 164.6K | ★ 291.2K |
| Earning Date | 04-29-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $858,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.26 | N/A |
| P/E Ratio | $85.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.73 | $23.18 |
| 52 Week High | $47.91 | $123.75 |
| Indicator | EIG | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 75.02 | 33.25 |
| Support Level | $41.01 | $70.35 |
| Resistance Level | $46.25 | $77.01 |
| Average True Range (ATR) | 0.91 | 4.84 |
| MACD | 0.17 | -1.35 |
| Stochastic Oscillator | 100.00 | 1.42 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations through its wholly owned subsidiaries.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.